Evasion of host immune defenses by human papillomavirus

Virus Research

Volumn 231, Issue , 2017, Pages 21-33

  Westrich, Joseph A ^a   Warren, Cody J ^a,b   Pyeon, Dohun ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adaptive immunity; APOBEC3; DNA methylation; Histone modification; HPV; Immune evasion; Innate immunity; Oncogene; Papillomavirus; Restriction factor; Tumor virus; Virus evolution

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; HISTONE; ONCOPROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CELL MIGRATION; CYTOPLASM; DNA METHYLATION; GENE EXPRESSION; HISTONE MODIFICATION; HOST RESISTANCE; IMMUNE EVASION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; VIRUS GENOME; WART VIRUS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; KERATINOCYTE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; PATHOLOGY; VIRION; VIROLOGY; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; CYTOSINE DEAMINASE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENOME, VIRAL; HISTONES; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; KERATINOCYTES; NF-KAPPA B; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIRION; VIRUS REPLICATION;

EID: 85011085596     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2016.11.023     Document Type: Review

References (182)

1. Abd Warif, N.M., Stoitzner, P., Leggatt, G.R., Mattarollo, S.R., Frazer, I.H., Hibma, M.H., Langerhans cell homeostasis and activation is altered in hyperplastic human papillomavirus type 16 E7 expressing epidermis. PLoS One, 10, 2015, e0127155.
2. Ahasan, M.M., Wakae, K., Wang, Z., Kitamura, K., Liu, G., Koura, M., Imayasu, M., Sakamoto, N., Hanaoka, K., Nakamura, M., Kyo, S., Kondo, S., Fujiwara, H., Yoshizaki, T., Mori, S., Kukimoto, I., Muramatsu, M., APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity. Biochem. Biophys. Res. Commun. 457 (2015), 295–299.
3. Amador-Molina, A., Hernandez-Valencia, J.F., Lamoyi, E., Contreras-Paredes, A., Lizano, M., Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 5 (2013), 2624–2642.
4. Antonsson, A., Payne, E., Hengst, K., McMillan, N.A., The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J. Interferon Cytokine Res. 26 (2006), 455–461.
5. Ashrafi, G.H., Tsirimonaki, E., Marchetti, B., O'Brien, P.M., Sibbet, G.J., Andrew, L., Campo, M.S., Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 21 (2002), 248–259.
6. Ashrafi, G.H., Haghshenas, M.R., Marchetti, B., O'Brien, P.M., Campo, M.S., E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int. J. Cancer 113 (2005), 276–283.
7. Ashrafi, G.H., Haghshenas, M., Marchetti, B., Campo, M.S., E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 119 (2006), 2105–2112.
8. Auluck, A., Hislop, G., Bajdik, C., Poh, C., Zhang, L., Rosin, M., Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 116 (2010), 2635–2644.
9. Badal, V., Chuang, L.S., Tan, E.H., Badal, S., Villa, L.L., Wheeler, C.M., Li, B.F., Bernard, H.U., CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J. Virol. 77 (2003), 6227–6234.
10. Badal, S., Badal, V., Calleja-Macias, I.E., Kalantari, M., Chuang, L.S., Li, B.F., Bernard, H.U., The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 324 (2004), 483–492.
11. Bellanger, S., Tan, C.L., Xue, Y.Z., Teissier, S., Thierry, F., Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am. J. Cancer. Res. 1 (2011), 373–389.
12. Bergot, A.S., Ford, N., Leggatt, G.R., Wells, J.W., Frazer, I.H., Grimbaldeston, M.A., HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells. PLoS Pathog., 10, 2014, e1004466.
13. Blagoveshchenskaya, A.D., Thomas, L., Feliciangeli, S.F., Hung, C.H., Thomas, G., HIV-1 nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 111 (2002), 853–866.
14. Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., De Rosa, L., Majolino, I., Novarese, L., Rocci, A., Gambella, M., Ciciarello, M., Scambia, G., Palumbo, A., Locatelli, F., De Cristofaro, R., Rutella, S., Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J. Transl. Med., 10, 2012, 247.
15. Bontkes, H.J., Ruizendaal, J.J., Kramer, D., Meijer, C.J., Hooijberg, E., Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol. Oncol. 96 (2005), 897–901.
16. Brady, G., Bowie, A.G., Innate immune activation of NFkappaB and its antagonism by poxviruses. Cytokine Growth Factor Rev. 25 (2014), 611–620.
17. Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M., Ryan, B.J., Weyer, J.L., van der Weyden, L., Fikrig, E., Adams, D.J., Xavier, R.J., Farzan, M., Elledge, S.J., The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139 (2009), 1243–1254.
18. Brigl, M., Brenner, M.B., CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22 (2004), 817–890.
19. Buck, C.B., Day, P.M., Thompson, C.D., Lubkowski, J., Lu, W., Lowy, D.R., Schiller, J.T., Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 1516–1521.
20. Burgers, W.a., Blanchon, L., Pradhan, S., de Launoit, Y., Kouzarides, T., Fuks, F., Viral oncoproteins target the DNA methyltransferases. Oncogene 26 (2007), 1650–1655.
21. Cai, X., Chiu, Y.H., Chen, Z.J., The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol. Cell 54 (2014), 289–296.
22. Campo, M.S., Graham, S.V., Cortese, M.S., Ashrafi, G.H., Araibi, E.H., Dornan, E.S., Miners, K., Nunes, C., Man, S., HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407 (2010), 137–142.
23. Chagas, B.S., Batista, M.V., Crovella, S., Gurgel, A.P., Silva Neto Jda, C., Serra, I.G., Amaral, C.M., Balbino, V.Q., Muniz, M.T., Freitas, A.C., Novel E6 and E7 oncogenes variants of human papillomavirus type 31 in Brazilian women with abnormal cervical cytology. Infect. Genet. Evol. 16 (2013), 13–18.
24. Chang, Y.E., Pena, L., Sen, G.C., Park, J.K., Laimins, L.A., Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 76 (2002), 8864–8874.
25. Chaturvedi, A.K., Engels E. a. Pfeiffer, R.M., Hernandez, B.Y., Xiao, W., Kim, E., Jiang, B., Goodman, M.T., Sibug-Saber, M., Cozen, W., Liu, L., Lynch, C.F., Wentzensen, N., Jordan, R.C., Altekruse, S., Anderson, W.F., Rosenberg, P.S., Gillison, M.L., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29 (2011), 4294–4301.
26. Chelico, L., Pham, P., Calabrese, P., Goodman, M.F., APOBEC3G DNA deaminase acts processively 3’ −> 5’ on single-stranded DNA. Nat. Struct. Mol. Biol. 13 (2006), 392–399.
27. Chen, H., Lilley, C.E., Yu, Q., Lee, D.V., Chou, J., Narvaiza, I., Landau, N.R., Weitzman, M.D., APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16 (2006), 480–485.
28. Chino, T., Draves, K.E., Clark, E.A., Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J. Leukoc. Biol. 86 (2009), 933–940.
29. Cho, Y.S., Kang, J.W., Cho, M., Cho, C.W., Lee, S., Choe, Y.K., Kim, Y., Choi, I., Park, S.N., Kim, S., Dinarello, C.A., Yoon, D.Y., Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett. 501 (2001), 139–145.
30. Chopjitt, P., Pientong, C., Bumrungthai, S., Kongyingyoes, B., Ekalaksananan, T., Activities of E6 protein of human papillomavirus 16 asian variant on miR-21 up-regulation and expression of human immune response genes. Asian Pac. J. Cancer Prev. 16 (2015), 3961–3968.
31. Christy, B.A., Scangos, G.A., In vitro methylation of bovine papillomavirus alters its ability to transform mouse cells. Mol. Cell. Biol. 6 (1986), 2910–2915.
32. Cicchini, L., Westrich, J.A., Xu, T., Vermeer, D.W., Berger, J.N., Clambey, E.T., Lee, D., Song, J.I., Lambert, P.F., Greer, R.O., Lee, J.H., Pyeon, D., Suppression of antitumor immune responses by human papillomavirus through epigenetic downregulation of CXCL14. MBio, 2016, 7.
33. Correia, S., Ventura, S., Parkhouse, R.M., Identification and utility of innate immune system evasion mechanisms of ASFV. Virus Res. 173 (2013), 87–100.
34. Da Silva, D.M., Woodham, A.W., Skeate, J.G., Rijkee, L.K., Taylor, J.R., Brand, H.E., Muderspach, L.I., Roman, L.D., Yessaian, A.A., Pham, H.Q., Matsuo, K., Lin, Y.G., McKee, G.M., Salazar, A.M., Kast, W.M., Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin. Immunol. 161 (2015), 197–208.
35. Daud, I.I., Scott, M.E., Ma, Y., Shiboski, S., Farhat, S., Moscicki, A.B., Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int. J. Cancer 128 (2011), 879–886.
36. De Andrea, M., Mondini, M., Azzimonti, B., Dell'Oste, V., Germano, S., Gaudino, G., Musso, T., Landolfo, S., Gariglio, M., Alpha- and betapapillomavirus E6/E7 genes differentially modulate pro-inflammatory gene expression. Virus Res. 124 (2007), 220–225.
37. den Boon, J.A., Pyeon, D., Wang, S.S., Horswill, M., Schiffman, M., Sherman, M., Zuna, R.E., Wang, Z., Hewitt, S.M., Pearson, R., Schott, M., Chung, L., He, Q., Lambert, P., Walker, J., Newton, M.A., Wentzensen, N., Ahlquist, P., Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E3255–3264.
38. Demoulin, S.A., Somja, J., Duray, A., Guenin, S., Roncarati, P., Delvenne, P.O., Herfs, M.F., Hubert, P.M., Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. Oncoimmunology, 4, 2015, e1008334.
39. DiGiuseppe, S., Bienkowska-Haba, M., Sapp, M., Human papillomavirus entry: hiding in a bubble. J. Virol., 2016.
40. DiMaio, D., Petti, L.M., The E5 proteins. Virology 445 (2013), 99–114.
41. Doan, T., Herd, K., Street, M., Bryson, G., Fernando, G., Lambert, P., Tindle, R., Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J. Virol. 73 (1999), 6166–6170.
42. Donaldson, J.G., Williams, D.B., Intracellular assembly and trafficking of MHC class I molecules. Traffic 10 (2009), 1745–1752.
43. Dunn, L.A., Evander, M., Tindle, R.W., Bulloch, A.L., de Kluyver, R.L., Fernando, G.J., Lambert, P.F., Frazer, I.H., Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 235 (1997), 94–103.
44. Dutta, S., Chakraborty, C., Mandal, R.K., Basu, P., Biswas, J., Roychoudhury, S., Panda, C.K., Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HLA-DQB1 and T-allele (rs16944) of IL-1beta −511 is associated with development of cervical carcinoma. Cancer Immunol. Immunother. 64 (2015), 843–851.
45. Dziduszko, A., Ozbun, M.A., Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes. J. Virol. 87 (2013), 7502–7515.
46. Fahey, L.M., Raff, A.B., Da Silva, D.M., Kast, W.M., A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J. Immunol. 183 (2009), 6151–6156.
47. Fausch, S.C., Da Silva, D.M., Rudolf, M.P., Kast, W.M., Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 169 (2002), 3242–3249.
48. Fausch, S.C., Da Silva, D.M., Kast, W.M., Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 63 (2003), 3478–3482.
49. Forman, D., de Martel, C., Lacey, C.J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., Franceschi, S., Global burden of human papillomavirus and related diseases. Vaccine 30:Suppl (5) (2012), F12–23.
50. Georgopoulos, N.T., Proffitt, J.L., Blair, G.E., Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 19 (2000), 4930–4935.
51. Ghosh, S., May, M.J., Kopp, E.B., NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998), 225–260.
52. Gildener-Leapman, N., Ferris, R.L., Bauman, J.E., Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 49 (2013), 1089–1096.
53. Gonzalez-Suarez, E., Sanz-Moreno, A., RANK as a therapeutic target in cancer. FEBS J. 283 (2016), 2018–2033.
54. Goulder, P.J., Phillips, R.E., Colbert, R.A., McAdam, S., Ogg, G., Nowak, M.A., Giangrande, P., Luzzi, G., Morgan, B., Edwards, A., McMichael, A.J., Rowland-Jones, S., Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3 (1997), 212–217.
55. Gram, A.M., Frenkel, J., Ressing, M.E., Inflammasomes and viruses: cellular defence versus viral offence. J. Gen. Virol. 93 (2012), 2063–2075.
56. Griffin, L.M., Cicchini, L., Pyeon, D., Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes. Virology 437 (2013), 12–19.
57. Guess, J.C., McCance, D.J., Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J. Virol. 79 (2005), 14852–14862.
58. Haller, O., Kochs, G., Weber, F., The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344 (2006), 119–130.
59. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.-J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., Dronca, R., Gangadhar, T.C., Patnaik, A., Zarour, H., Joshua, A.M., Gergich, K., Elassaiss-Schaap, J., Algazi, A., Mateus, C., Boasberg, P., Tumeh, P.C., Chmielowski, B., Ebbinghaus, S.W., Li, X.N., Kang, S.P., Ribas, A., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
60. Handisurya, A., Day, P.M., Thompson, C.D., Bonelli, M., Lowy, D.R., Schiller, J.T., Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog., 10, 2014, e1004314.
61. Hasan, U.A., Zannetti, C., Parroche, P., Goutagny, N., Malfroy, M., Roblot, G., Carreira, C., Hussain, I., Muller, M., Taylor-Papadimitriou, J., Picard, D., Sylla, B.S., Trinchieri, G., Medzhitov, R., Tommasino, M., The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med. 210 (2013), 1369–1387.
62. Henn, M.R., Boutwell, C.L., Charlebois, P., Lennon, N.J., Power, K.A., Macalalad, A.R., Berlin, A.M., Malboeuf, C.M., Ryan, E.M., Gnerre, S., Zody, M.C., Erlich, R.L., Green, L.M., Berical, A., Wang, Y., Casali, M., Streeck, H., Bloom, A.K., Dudek, T., Tully, D., Newman, R., Axten, K.L., Gladden, A.D., Battis, L., Kemper, M., Zeng, Q., Shea, T.P., Gujja, S., Zedlack, C., Gasser, O., Brander, C., Hess, C., Gunthard, H.F., Brumme, Z.L., Brumme, C.J., Bazner, S., Rychert, J., Tinsley, J.P., Mayer, K.H., Rosenberg, E., Pereyra, F., Levin, J.Z., Young, S.K., Jessen, H., Altfeld, M., Birren, B.W., Walker, B.D., Allen, T.M., Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog., 8, 2012, e1002529.
63. Herdman, M.T., Pett, M.R., Roberts, I., Alazawi, W.O., Teschendorff, A.E., Zhang, X.Y., Stanley, M.A., Coleman, N., Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27 (2006), 2341–2353.
64. Hewitt, E.W., The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110 (2003), 163–169.
65. Hino, R., Uozaki, H., Murakami, N., Ushiku, T., Shinozaki, A., Ishikawa, S., Morikawa, T., Nakaya, T., Sakatani, T., Takada, K., Fukayama, M., Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69 (2009), 2766–2774.
66. Hochedlinger, K., Plath, K., Epigenetic reprogramming and induced pluripotency. Development 136 (2009), 509–523.
67. Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D.R., Latz, E., Fitzgerald, K.A., AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458 (2009), 514–518.
68. Howley, P.M., Warts, cancer and ubiquitylation: lessons from the papillomaviruses. Trans. Am. Clin. Climatol. Assoc. 117 (2006), 113–126 discussion 126-117.
69. Huang, S.M., McCance, D.J., Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 76 (2002), 8710–8721.
70. Hultquist, J.F., Lengyel, J.A., Refsland, E.W., LaRue, R.S., Lackey, L., Brown, W.L., Harris, R.S., Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85 (2011), 11220–11234.
71. Jackson, S.E., Mason, G.M., Wills, M.R., Human cytomegalovirus immunity and immune evasion. Virus Res. 157 (2011), 151–160.
72. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., Navaratnam, N., An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 (2002), 285–296.
73. Kalantari, M., Calleja-Macias, I.E., Tewari, D., Hagmar, B., Lie, K., Barrera-Saldana, H.A., Wiley, D.J., Bernard, H.U., Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J. Virol. 78 (2004), 12762–12772.
74. Kalantari, M., Chase, D.M., Tewari, K.S., Bernard, H.U., Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J. Med. Virol. 82 (2010), 311–320.
75. Karim, R., Tummers, B., Meyers, C., Biryukov, J.L., Alam, S., Backendorf, C., Jha, V., Offringa, R., van Ommen, G.J., Melief, C.J., Guardavaccaro, D., Boer, J.M., van der Burg, S.H., Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog., 9, 2013, e1003384.
76. Karlin, S., Doerfler, W., Cardon, L.R., Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses. J. Virol. 68 (1994), 2889–2897.
77. Kerur, N., Veettil, M.V., Sharma-Walia, N., Bottero, V., Sadagopan, S., Otageri, P., Chandran, B., IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe 9 (2011), 363–375.
78. Kim, K.C., Friso, S., Choi, S.W., DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J. Nutr. Biochem. 20 (2009), 917–926.
79. Kleine-Lowinski, K., Rheinwald, J.G., Fichorova, R.N., Anderson, D.J., Basile, J., Munger, K., Daly, C.M., Rosl, F., Rollins, B.J., Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int. J. Cancer 107 (2003), 407–415.
80. Kouzarides, T., Chromatin modifications and their function. Cell 128 (2007), 693–705.
81. Kumagai, Y., Takeuchi, O., Akira, S., TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 60 (2008), 795–804.
82. LaRue, R.S., Andresdottir, V., Blanchard, Y., Conticello, S.G., Derse, D., Emerman, M., Greene, W.C., Jonsson, S.R., Landau, N.R., Lochelt, M., Malik, H.S., Malim, M.H., Munk, C., O'Brien, S.J., Pathak, V.K., Strebel, K., Wain-Hobson, S., Yu, X.F., Yuhki, N., Harris, R.S., Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83 (2009), 494–497.
83. Lau, L., Gray, E.E., Brunette, R.L., Stetson, D.B., DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science 350 (2015), 568–571.
84. Lauring, A.S., Frydman, J., Andino, R., The role of mutational robustness in RNA virus evolution. Nat. Rev. Microbiol. 11 (2013), 327–336.
85. Lee, M.S., Kim, Y.J., Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem 76 (2007), 447–480.
86. Lee, S.Y., Huang, Z., Kang, T.H., Soong, R.S., Knoff, J., Axenfeld, E., Wang, C., Alvarez, R.D., Chen, C.S., Hung, C.F., Wu, T.C., Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl) 91 (2013), 1221–1231.
87. Lenz, P., Day, P.M., Pang, Y.Y., Frye, S.A., Jensen, P.N., Lowy, D.R., Schiller, J.T., Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166 (2001), 5346–5355.
88. Lenz, P., Lowy, D.R., Schiller, J.T., Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur. J. Immunol. 35 (2005), 1548–1556.
89. Li, S., Labrecque, S., Gauzzi, M.C., Cuddihy, A.R., Wong, A.H., Pellegrini, S., Matlashewski, G.J., Koromilas, A.E., The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 18 (1999), 5727–5737.
90. Li, W., Deng, X.M., Wang, C.X., Zhang, X., Zheng, G.X., Zhang, J., Feng, J.B., Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression. Int. J. Gynecol. Cancer 20 (2010), 227–232.
91. Li, X., Shu, C., Yi, G., Chaton, C.T., Shelton, C.L., Diao, J., Zuo, X., Kao, C.C., Herr, A.B., Li, P., Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity 39 (2013), 1019–1031.
92. Lipovsky, A., Popa, A., Pimienta, G., Wyler, M., Bhan, A., Kuruvilla, L., Guie, M.A., Poffenberger, A.C., Nelson, C.D., Atwood, W.J., DiMaio, D., Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 7452–7457.
93. Liu, X., Wang, Y., Wang, X., Sun, Z., Li, L., Tao, Q., Luo, B., Epigenetic silencing of WNT5A in Epstein-Barr virus-associated gastric carcinoma. Arch. Virol 158 (2013), 123–132.
94. Lo Cigno, I., De Andrea, M., Borgogna, C., Albertini, S., Landini, M.M., Peretti, A., Johnson, K.E., Chandran, B., Landolfo, S., Gariglio, M., The nuclear DNA sensor IFI16 acts as a restriction factor for human papillomavirus replication through epigenetic modifications of the viral promoters. J. Virol. 89 (2015), 7506–7520.
95. Matsumoto, K., Leggatt, G.R., Zhong, J., Liu, X., de Kluyver, R.L., Peters, T., Fernando, G.J., Liem, A., Lambert, P.F., Frazer, I.H., Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J. Natl. Cancer Inst. 96 (2004), 1611–1619.
96. McBride, A.A., Romanczuk, H., Howley, P.M., The papillomavirus E2 regulatory proteins. J. Biol. Chem. 266 (1991), 18411–18414.
97. McBride, A.A., The papillomavirus E2 proteins. Virology 445 (2013), 57–79.
98. McLaughlin-Drubin, M.E., Huh, K.W., Munger, K., Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 82 (2008), 8695–8705.
99. McLaughlin-Drubin, M.E., Crum, C.P., Munger, K., Human papillomavirus E7 oncoprotein induces KDM6A and KDM6 B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 2130–2135.
100. Mirabello, L., Sun, C., Ghosh, A., Rodriguez, A.C., Schiffman, M., Wentzensen, N., Hildesheim, A., Herrero, R., Wacholder, S., Lorincz, A., Burk, R.D., Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J. Natl. Cancer Inst. 104 (2012), 556–565.
101. Mittal, D., Kassianos, A.J., Tran, L.S., Bergot, A.S., Gosmann, C., Hofmann, J., Blumenthal, A., Leggatt, G.R., Frazer, I.H., Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J. Invest. Dermatol. 133 (2013), 2686–2694.
102. Miura, S., Kawana, K., Schust, D.J., Fujii, T., Yokoyama, T., Iwasawa, Y., Nagamatsu, T., Adachi, K., Tomio, A., Tomio, K., Kojima, S., Yasugi, T., Kozuma, S., Taketani, Y., CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J. Virol. 84 (2010), 11614–11623.
103. Munn, D.H., Mellor, A.L., Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34 (2013), 137–143.
104. Narayan, S., Choyce, A., Linedale, R., Saunders, N.A., Dahler, A., Chan, E., Fernando, G.J., Frazer, I.H., Leggatt, G.R., Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4 + CD25+ T cells. Eur. J. Immunol. 39 (2009), 481–490.
105. Narvaiza, I., Linfesty, D.C., Greener, B.N., Hakata, Y., Pintel, D.J., Logue, E., Landau, N.R., Weitzman, M.D., Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog., 5, 2009, e1000439.
106. Niebler, M., Qian, X., Hofler, D., Kogosov, V., Kaewprag, J., Kaufmann, A.M., Ly, R., Bohmer, G., Zawatzky, R., Rosl, F., Rincon-Orozco, B., Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog., 9, 2013, e1003536.
107. Novick, D., Kim, S.H., Fantuzzi, G., Reznikov, L.L., Dinarello, C.A., Rubinstein, M., Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999), 127–136.
108. Oosterhuis, K., Aleyd, E., Vrijland, K., Schumacher, T.N., Haanen, J.B., Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum. Gene Ther. 23 (2012), 1301–1312.
109. Orange, J.S., Natural killer cell deficiency. J. Allergy Clin. Immunol. 132 (2013), 515–525 (quiz 526).
110. Pacini, L., Savini, C., Ghittoni, R., Saidj, D., Lamartine, J., Hasan, U.A., Accardi, R., Tommasino, M., Downregulation of toll-Like receptor 9 expression by beta human papillomavirus 38 and implications for cell cycle control. J. Virol. 89 (2015), 11396–11405.
111. Park, J.S., Kim, E.J., Kwon, H.J., Hwang, E.S., Namkoong, S.E., Um, S.J., Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein: implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275 (2000), 6764–6769.
112. Perea, S.E., Massimi, P., Banks, L., Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int. J. Mol. Med. 5 (2000), 661–666.
113. Perreira, J.M., Chin, C.R., Feeley, E.M., Brass, A.L., IFITMs restrict the replication of multiple pathogenic viruses. J. Mol. Biol. 425 (2013), 4937–4955.
114. Pfeiffer, J.K., Kirkegaard, K., Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog., 1, 2005, e11.
115. Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., Ochs, K., Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front. Immunol., 5, 2014, 673.
116. Poeck, H., Ruland, J., From virus to inflammation: mechanisms of RIG-I-induced IL-1beta production. Eur. J. Cell Biol. 91 (2012), 59–64.
117. Pyeon, D., Pearce, S.M., Lank, S.M., Ahlquist, P., Lambert, P.F., Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog., 5, 2009, e1000318.
118. Qu, L., Lemon, S.M., Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin. Liver Dis. 30 (2010), 319–332.
119. Reinholz, M., Kawakami, Y., Salzer, S., Kreuter, A., Dombrowski, Y., Koglin, S., Kresse, S., Ruzicka, T., Schauber, J., HPV16 activates the AIM2 inflammasome in keratinocytes. Arch. Dermatol. Res. 305 (2013), 723–732.
120. Reiser, J., Hurst, J., Voges, M., Krauss, P., Munch, P., Iftner, T., Stubenrauch, F., High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 85 (2011), 11372–11380.
121. Ressing, M.E., Sette, A., Brandt, R.M., Ruppert, J., Wentworth, P.A., Hartman, M., Oseroff, C., Grey, H.M., Melief, C.J., Kast, W.M., Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154 (1995), 5934–5943.
122. Richards, K.H., Doble, R., Wasson, C.W., Haider, M., Blair, G.E., Wittmann, M., Macdonald, A., Human papillomavirus E7 oncoprotein increases production of the anti-inflammatory interleukin-18 binding protein in keratinocytes. J. Virol. 88 (2014), 4173–4179.
123. Richards, K.H., Wasson, C.W., Watherston, O., Doble, R., Blair, G.E., Wittmann, M., Macdonald, A., The human papillomavirus (HPV) E7 protein antagonises an Imiquimod-induced inflammatory pathway in primary human keratinocytes. Sci. Rep., 5, 2015, 12922.
124. Rincon-Orozco, B., Halec, G., Rosenberger, S., Muschik, D., Nindl, I., Bachmann, A., Ritter, T.M., Dondog, B., Ly, R., Bosch, F.X., Zawatzky, R., Rosl, F., Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 69 (2009), 8718–8725.
125. Robertson, K.D., DNA methylation and human disease. Nat. Rev. Genet. 6 (2005), 597–610.
126. Roman, A., Munger, K., The papillomavirus E7 proteins. Virology 445 (2013), 138–168.
127. Ronco, L.V., Karpova, A.Y., Vidal, M., Howley, P.M., Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12 (1998), 2061–2072.
128. Rosl, F., Arab, A., Klevenz, B., zur Hausen, H., The effect of DNA methylation on gene regulation of human papillomaviruses. J. Gen. Virol. 74:Pt 5 (1993), 791–801.
129. Rudolf, M.P., Fausch, S.C., Da Silva, D.M., Kast, W.M., Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166 (2001), 5917–5924.
130. Sanjuan, R., Nebot, M.R., Chirico, N., Mansky, L.M., Belshaw, R., Viral mutation rates. J. Virol. 84 (2010), 9733–9748.
131. Schaerli, P., Willimann, K., Ebert, L.M., Walz, A., Moser, B., Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23 (2005), 331–342.
132. Schelhaas, M., Shah, B., Holzer, M., Blattmann, P., Kuhling, L., Day, P.M., Schiller, J.T., Helenius, A., Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog., 8, 2012, e1002657.
133. Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., Wacholder, S., Human papillomavirus and cervical cancer. Lancet 370 (2007), 890–907.
134. Schmidt, S.V., Schultze, J.L., New insights into IDO biology in bacterial and viral infections. Front. Immunol., 5, 2014, 384.
135. Seitz, H., Schmitt, M., Bohmer, G., Kopp-Schneider, A., Muller, M., Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int. J. Cancer 132 (2013), E139–148.
136. Shalginskikh, N., Poleshko, A., Skalka, A.M., Katz, R.A., Retroviral DNA methylation and epigenetic repression are mediated by the antiviral host protein Daxx. J. Virol. 87 (2013), 2137–2150.
137. Sheehy, A.M., Gaddis, N.C., Choi, J.D., Malim, M.H., Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002), 646–650.
138. Shurin, G.V., Ferris, R.L., Tourkova, I.L., Perez, L., Lokshin, A., Balkir, L., Collins, B., Chatta, G.S., Shurin, M.R., Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174 (2005), 5490–5498 Baltimore, Md 1950.
139. Silmon de Monerri, N.C., Kim, K., Pathogens hijack the epigenome: a new twist on host-pathogen interactions. Am. J. Pathol. 184 (2014), 897–911.
140. Stanley, M.A., Epithelial cell responses to infection with human papillomavirus. Clin. Microbiol. Rev. 25 (2012), 215–222.
141. Stein, A.P., Saha, S., Yu, M., Kimple, R.J., Lambert, P.F., Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem. Res. Toxicol. 27 (2014), 462–469.
142. Stenglein, M.D., Burns, M.B., Li, M., Lengyel, J., Harris, R.S., APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17 (2010), 222–229.
143. Sun, L., Wu, J., Du, F., Chen, X., Chen, Z.J., Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339 (2013), 786–791.
144. Sunthamala, N., Thierry, F., Teissier, S., Pientong, C., Kongyingyoes, B., Tangsiriwatthana, T., Sangkomkamhang, U., Ekalaksananan, T., E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-kappa transcription in keratinocytes. PLoS One, 9, 2014, e91473.
145. Tanaka, Y., Chen, Z.J., STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal., 5, 2012, ra20.
146. Timm, J., Lauer, G.M., Kavanagh, D.G., Sheridan, I., Kim, A.Y., Lucas, M., Pillay, T., Ouchi, K., Reyor, L.L., Schulze zur Wiesch, J., Gandhi, R.T., Chung, R.T., Bhardwaj, N., Klenerman, P., Walker, B.D., Allen, T.M., CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 200 (2004), 1593–1604.
147. Tindle, R.W., Herd, K., Doan, T., Bryson, G., Leggatt, G.R., Lambert, P., Frazer, I.H., Street, M., Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J. Virol. 75 (2001), 5985–5997.
148. Tummers, B., Goedemans, R., Pelascini, L.P., Jordanova, E.S., van Esch, E.M., Meyers, C., Melief, C.J., Boer, J.M., van der Burg, S.H., The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFkappaB activation. Nat. Commun., 6, 2015, 6537.
149. Uberoi, A., Yoshida, S., Frazer, I.H., Pitot, H.C., Lambert, P.F., Role of ultraviolet radiation in papillomavirus-induced disease. PLoS Pathog., 12, 2016, e1005664.
150. Um, S.J., Rhyu, J.W., Kim, E.J., Jeon, K.C., Hwang, E.S., Park, J.S., Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett. 179 (2002), 205–212.
151. Unterholzner, L., Keating, S.E., Baran, M., Horan, K.A., Jensen, S.B., Sharma, S., Sirois, C.M., Jin, T., Latz, E., Xiao, T.S., Fitzgerald, K.A., Paludan, S.R., Bowie, A.G., IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11 (2010), 997–1004.
152. Upadhyay, M., Vivekanandan, P., Depletion of CpG dinucleotides in papillomaviruses and polyomaviruses: a role for divergent evolutionary pressures. PLoS One, 10, 2015, e0142368.
153. Upadhyay, M., Samal, J., Kandpal, M., Vasaikar, S., Biswas, B., Gomes, J., Vivekanandan, P., CpG dinucleotide frequencies reveal the role of host methylation capabilities in parvovirus evolution. J. Virol. 87 (2013), 13816–13824.
154. van Baren, N., Van den Eynde, B.J., Tryptophan-degrading enzymes in tumoral immune resistance. Front. Immunol., 6, 2015, 34.
155. van de Weijer, M.L., Luteijn, R.D., Wiertz, E.J., Viral immune evasion: lessons in MHC class I antigen presentation. Semin. Immunol. 27 (2015), 125–137.
156. Van Doorslaer, K., Evolution of the papillomaviridae. Virology 445 (2013), 11–20.
157. Vande Pol, S.B., Klingelhutz, A.J., Papillomavirus E6 oncoproteins. Virology 445 (2013), 115–137.
158. Vandermark, E.R., Deluca, K.A., Gardner, C.R., Marker, D.F., Schreiner, C.N., Strickland, D.A., Wilton, K.M., Mondal, S., Woodworth, C.D., Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology 425 (2012), 53–60.
159. Vartanian, J.P., Guetard, D., Henry, M., Wain-Hobson, S., Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320 (2008), 230–233.
160. Vignuzzi, M., Stone, J.K., Arnold, J.J., Cameron, C.E., Andino, R., Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439 (2006), 344–348.
161. Viscidi, R.P., Schiffman, M., Hildesheim, A., Herrero, R., Castle, P.E., Bratti, M.C., Rodriguez, A.C., Sherman, M.E., Wang, S., Clayman, B., Burk, R.D., Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol. Biomarkers Prev. 13 (2004), 324–327.
162. Vossen, M.T., Westerhout, E.M., Soderberg-Naucler, C., Wiertz, E.J., Viral immune evasion: a masterpiece of evolution. Immunogenetics 54 (2002), 527–542.
163. Wang, Z., Wakae, K., Kitamura, K., Aoyama, S., Liu, G., Koura, M., Monjurul, A.M., Kukimoto, I., Muramatsu, M., APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J. Virol. 88 (2014), 1308–1317.
164. Warren, C.J., Pyeon, D., APOBEC3 in papillomavirus restriction: evolution and cancer progression. Oncotarget 6 (2015), 39385–39386.
165. Warren, C.J., Griffin, L.M., Little, A.S., Huang, I.C., Farzan, M., Pyeon, D., The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One, 9, 2014, e96579.
166. Warren, C., Van Doorslaer, C., Pandey, A., Espinosa, J., Pyeon, D., Role of the host restriction factor APOBEC3 on papillomavirus evolution. Virus Evol., 2015.
167. Warren, C.J., Xu, T., Guo, K., Griffin, L.M., Westrich J. a. Lee, D., Lambert, P.F., Santiago, M.L., Pyeon, D., APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89 (2015), 688–702.
168. Waterhouse, P.M., Wang, M.B., Lough, T., Gene silencing as an adaptive defence against viruses. Nature 411 (2001), 834–842.
169. Welters, M.J., Kenter, G.G., Piersma, S.J., Vloon, A.P., Lowik, M.J., Berends-van der Meer, D.M., Drijfhout, J.W., Valentijn, A.R., Wafelman, A.R., Oostendorp, J., Fleuren, G.J., Offringa, R., Melief, C.J., van der Burg, S.H., Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14 (2008), 178–187.
170. Wiens, M.E., Smith, J.G., Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection. J. Virol. 89 (2015), 2866–2874.
171. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.-A., Reed, K., Burke, M.M., Caldwell, A., Kronenberg, S.A., Agunwamba, B.U., Zhang, X., Lowy, I., Inzunza, H.D., Feely, W., Horak, C.E., Hong, Q., Korman, A.J., Wigginton, J.M., Gupta, A., Sznol, M., Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
172. Woo, H.J., Reifman, J., A quantitative quasispecies theory-based model of virus escape mutation under immune selection. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 12980–12985.
173. Woo, Y.L., Sterling, J., Damay, I., Coleman, N., Crawford, R., van der Burg, S.H., Stanley, M., Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 115 (2008), 1616–1621 discussion 1621-1612.
174. Woodham, A.W., Da Silva, D.M., Skeate, J.G., Raff, A.B., Ambroso, M.R., Brand, H.E., Isas, J.M., Langen, R., Kast, W.M., The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One, 7, 2012, e43519.
175. Woodham, A.W., Raff, A.B., Raff, L.M., Da Silva, D.M., Yan, L., Skeate, J.G., Wong, M.K., Lin, Y.G., Kast, W.M., Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J. Immunol. 192 (2014), 4748–4757.
176. Wu, S., Hu, G., Chen, J., Xie, G., Interleukin 1beta and interleukin 1 receptor antagonist gene polymorphisms and cervical cancer: a meta-analysis. Int. J. Gynecol. Cancer 24 (2014), 984–990.
177. Xu, J., Yin, Z., Cao, S., Gao, W., Liu, L., Yin, Y., Liu, P., Shu, Y., Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One, 8, 2013, e63654.
178. Yang, R., Murillo, F.M., Cui, H., Blosser, R., Uematsu, S., Takeda, K., Akira, S., Viscidi, R.P., Roden, R.B., Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J. Virol. 78 (2004), 11152–11160.
179. Yang, R., Wheeler, C.M., Chen, X., Uematsu, S., Takeda, K., Akira, S., Pastrana, D.V., Viscidi, R.P., Roden, R.B., Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J. Virol. 79 (2005), 6741–6750.
180. Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D., Landau, N.R., APOBEC3 B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 (2004), 53379–53386.
181. Zhang, B., Li, P., Wang, E., Brahmi, Z., Dunn, K.W., Blum, J.S., Roman, A., The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology 310 (2003), 100–108.
182. Zheng, Y.H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., Peterlin, B.M., Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 (2004), 6073–6076.